Amesite CEO buys stock and warrants in AMST
Amesite Inc. director and chief executive officer Ann Marie Sastry reported buying additional equity on April 28, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amesite Inc. director and chief executive officer Ann Marie Sastry reported buying additional equity on April 28, 2026. She purchased 174,216 shares of common stock at $1.435 per share in a private placement pursuant to a securities purchase agreement and now holds 1,049,647 common shares directly. On the same date, she also acquired Series A-1 and Series A-2 warrants, each covering 174,216 underlying common shares at a $1.435 exercise price, with expirations on April 28, 2031 and October 28, 2027, respectively.
Insider Trade Summary
Net Buyer: 522,648 shares
Net Buy
3 txns
Insider
Sastry Ann Marie
Role
CHIEF EXECUTIVE OFFICER
Bought
522,648 shs ($250K)
Increase in Position
19.9%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Series A-1 Warrants (right to buy) | 174,216 | $0.00 | $0.00 |
| Purchase | Series A-2 Warrants (right to buy) | 174,216 | $0.00 | $0.00 |
| Purchase | Common Stock | 174,216 | $1.435 | $250K |
Holdings After Transaction:
Series A-1 Warrants (right to buy) — 174,216 warrants (Direct);
Series A-2 Warrants (right to buy) — 174,216 warrants (Direct);
Common Stock — 1,049,647 shares (Direct)
Holdings Before and After:
Series A-1 Warrants (right to buy), 0 to 174,216 warrants (Direct);
Series A-2 Warrants (right to buy), 0 to 174,216 warrants (Direct);
Common Stock, 875,431 to 1,049,647 shares (Direct)
Other Insiders: 1 other insider reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (1)
- F1. The shares were purchased in a private placement transaction pursuant to a securities purchase agreement. For more information relating to the offering pursuant to which the reported shares were purchased, please refer to the 424(b)(5) prospectus supplement filed by Amesite Inc. with the SEC on April 28, 2026.
Key Figures
Common shares purchased: 174,216 shares
Purchase price per share: $1.435 per share
Common shares after transaction: 1,049,647 shares
+5 more
8 metrics
Common shares purchased
174,216 shares
Common Stock bought on April 28, 2026 at $1.435
Purchase price per share
$1.435 per share
Price for 174,216 common shares on April 28, 2026
Common shares after transaction
1,049,647 shares
Total Amesite common stock directly held after April 28, 2026
Series A-1 warrants acquired
174,216 warrants
Series A-1 Warrants, each for one common share
Series A-2 warrants acquired
174,216 warrants
Series A-2 Warrants, each for one common share
Warrant exercise price
$1.435 per share
Exercise price for Series A-1 and A-2 warrants
Series A-2 warrant expiration
October 28, 2027
Expiration date of Series A-2 Warrants
Series A-1 warrant expiration
April 28, 2031
Expiration date of Series A-1 Warrants
Key Terms
private placement transaction, securities purchase agreement, 424(b)(5) prospectus supplement, Series A-1 Warrants, +2 more
6 terms
private placement transaction financial
"The shares were purchased in a private placement transaction pursuant to a securities purchase agreement."
securities purchase agreement financial
"The shares were purchased in a private placement transaction pursuant to a securities purchase agreement."
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
424(b)(5) prospectus supplement regulatory
"please refer to the 424(b)(5) prospectus supplement filed by Amesite Inc. with the SEC on April 28, 2026."
Series A-1 Warrants financial
"Series A-1 Warrants (right to buy)"
Series A-1 warrants are tradable instruments that give their holder the right, but not the obligation, to buy a company’s shares at a preset price for a limited time; they are typically issued alongside a specific financing round labeled “Series A-1.” Think of them like a coupon that lets an investor buy stock at a locked-in price later — if the company’s share price rises above that price the coupon becomes valuable, otherwise it may expire worthless. For investors they matter because exercising warrants can increase potential upside while also diluting existing shareholders and affecting future ownership percentages and share value.
Series A-2 Warrants financial
"Series A-2 Warrants (right to buy)"
Series A-2 warrants are a specific class of long‑term options issued by a company that give the holder the right to buy a set number of shares at a pre‑agreed price. Think of them as a coupon for future stock purchases: they can add potential value for the holder if the share price rises, but they also represent potential dilution for existing shareholders and can affect an investor’s ownership and returns when exercised or converted.
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Amesite Inc. (AMST) report in this Form 4?
Amesite Inc. reported that CEO and director Ann Marie Sastry bought 174,216 common shares and acquired Series A-1 and A-2 warrants, each for 174,216 underlying shares, all dated April 28, 2026, as part of a private placement transaction.
What are the key terms of Amesite (AMST) Series A-1 and A-2 warrants acquired by the CEO?
The CEO acquired Series A-1 and Series A-2 warrants, each covering 174,216 underlying Amesite common shares at a $1.435 exercise price. The Series A-2 warrants expire on October 28, 2027, and the Series A-1 warrants expire on April 28, 2031.
Was Amesite’s CEO open-market buying or participating in a private placement?
Although coded as purchases, the footnote specifies the CEO’s transactions were part of a private placement under a securities purchase agreement. The footnote directs investors to Amesite’s 424(b)(5) prospectus supplement filed on April 28, 2026, for additional offering details.
How many total securities did Amesite’s CEO acquire in this Form 4 period?
Across all reported transactions, the CEO acquired 174,216 common shares and two warrant series, each for 174,216 underlying shares. Transaction summary data shows three buy transactions totaling 522,648 units, including both common stock and warrant positions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
